Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABR Combined With Sintilimab for MSS Oligometastatic Colorectal Cancer
NCT04535024Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in colorectal cancer (CRC), sponsored by Fudan University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04535024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535024.